The abstract is read at the publisher; the summary is JClub's.
In HFrEF patients (LVEF ≤40%) on contemporary therapy, hydralazine–isosorbide dinitrate did not reduce the composite rate of heart failure events or death (30.6% vs 30.5%).
- Why it matters: The trial addressed whether H-ISDN’s earlier benefits would translate to modern, randomized care for chronic HFrEF patients, targeting hospitalization, urgent IV/metolazone visits, advanced interventions, or mortality.
- What they did: In a multicentre, randomized, double-blind, placebo-controlled study at 23 Danish hospitals, 592 predominantly White patients received hydralazine 75 mg/isosorbide dinitrate 40 mg three times daily versus placebo, followed for a mean of 3.7 years.
- The result: The primary composite endpoint was similar between groups (HR 0.90; 95% CI 0.67–1.21; P=.48), with deaths numerically fewer (57 vs 72; HR 0.72; 95% CI 0.51–1.02) but not statistically significant.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.